Ignite Creation Date:
2024-05-06 @ 6:27 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05669794
Status:
RECRUITING
Last Update Posted:
2024-06-03
First Post:
2022-12-21
Brief Title:
An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
Real-world Effectiveness and Use of UPaDAcitinib in Patients With moderaTE-to-severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
UPDATE
Brief Summary:
Atopic dermatitis AD is a skin condition that may cause a rash and itching due to inflammation of the skin This study will assess how effective upadacitinib is in treating AD
Upadacitinib is an approved drug for treating AD Approximately 300 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in France
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection
There is expected to be no additional burden for participants in this trial Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Upadacitinib is an approved drug for treating AD Approximately 300 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in France
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection
There is expected to be no additional burden for participants in this trial Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None